Home » Topics » BioWorld Science, Respiratory

BioWorld Science, Respiratory
RSS

Phase I data pave way for phase II evaluation of PureTech's LYT-100

Nov. 18, 2020

Vicore Pharma opens enrollment in phase II study of C-21 for IPF

Nov. 16, 2020

FDA allows IND application for AV-001 in hospitalized patients with COVID-19

Nov. 13, 2020

Phase III NAVIGATOR study of tezepelumab in severe asthma meets primary endpoint

Nov. 10, 2020

Dizal (Jiangsu) Pharmaceutical presents new JAK1 inhibitors

Nov. 6, 2020

FDA approves Bronchitol inhalation powder for patients with cystic fibrosis

Nov. 4, 2020

AstraZeneca reports data from steroid-sparing trial of Fasenra in severe asthma

Nov. 2, 2020

Aveni Foundation initiates phase I/II study of DeltaRex-G for COVID-19

Oct. 30, 2020

Boehringer Ingelheim initiates phase II study of BI-764198 in patients with COVID-19

Oct. 29, 2020

Xintela's XSTEM shows therapeutic effect in preclinical pig model of ARDS

Oct. 29, 2020

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 10, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for June 9, 2026
Skape Bio unlocks GPCR targets with de novo-designed miniproteins
BioWorld
Modulating G protein-coupled receptors (GPCRs) is one of the major challenges in biomedicine. These are flexible proteins with small, deep binding pockets. The...
Antares Therapeutics divulges new CDK2/cyclin E1 inhibitors
BioWorld Science
Antares Therapeutics Inc. has reported new CDK2/cyclin E1 inhibitors potentially useful for the treatment of cancer.
Empire Discovery Institute, Univ. of Rochester identify IRAK inhibitors
BioWorld Science
Empire Discovery Institute and the University of Rochester have discovered new interleukin-1 receptor-associated kinase 1 (IRAK-1) and/or IRAK-4 inhibitors...